Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Deferred Revenue (2016 - 2025)

AC Immune has reported Current Deferred Revenue over the past 11 years, most recently at $104.7 million for Q4 2025.

  • Quarterly Current Deferred Revenue rose 7.87% to $104.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.7 million through Dec 2025, up 7.87% year-over-year, with the annual reading at $104.7 million for FY2025, 7.87% up from the prior year.
  • Current Deferred Revenue was $104.7 million for Q4 2025 at AC Immune, up from $97.1 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $777.6 million in Q4 2021 and troughed at $18467.3 in Q3 2024.
  • The 5-year median for Current Deferred Revenue is $542579.3 (2022), against an average of $135.0 million.
  • Year-over-year, Current Deferred Revenue skyrocketed 229626.92% in 2021 and then plummeted 99.96% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $777.6 million in 2021, then crashed by 99.92% to $609318.9 in 2022, then skyrocketed by 25432.59% to $155.6 million in 2023, then plummeted by 37.59% to $97.1 million in 2024, then rose by 7.87% to $104.7 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Current Deferred Revenue are $104.7 million (Q4 2025), $97.1 million (Q4 2024), and $18467.3 (Q3 2024).